This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.
Voluntary and signed informed consent, good compliance
Age: ≥18 years old (at the time of signing the informed consent); expected survival time greater than 3 months.
Myelodysplastic Syndromes (MDS)
Major organ functions are normal.
Diagnosis of or current concomitant malignancy within 3 years prior to the first dose;
Presence of multiple factors affecting oral drug intake and/or absorption;
Major surgical procedures or significant traumatic injuries within 28 days prior to the first dose;
History of arterial/venous thrombotic events within 6 months prior to the first dose;